Chartwell Investment Partners LLC trimmed its stake in GlaxoSmithKline plc (NYSE:GSK) by 24.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 314,553 shares of the pharmaceutical company’s stock after selling 103,470 shares during the period. Chartwell Investment Partners LLC’s holdings in GlaxoSmithKline were worth $12,680,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Fisher Asset Management LLC increased its stake in shares of GlaxoSmithKline by 2.9% in the 2nd quarter. Fisher Asset Management LLC now owns 13,824,123 shares of the pharmaceutical company’s stock worth $557,250,000 after purchasing an additional 395,779 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in GlaxoSmithKline by 4.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,974,190 shares of the pharmaceutical company’s stock worth $240,820,000 after buying an additional 271,819 shares during the period. Northern Trust Corp boosted its holdings in GlaxoSmithKline by 10.6% in the 1st quarter. Northern Trust Corp now owns 3,206,664 shares of the pharmaceutical company’s stock worth $125,284,000 after buying an additional 306,441 shares during the period. Equity Investment Corp boosted its holdings in GlaxoSmithKline by 52.6% in the 1st quarter. Equity Investment Corp now owns 3,188,745 shares of the pharmaceutical company’s stock worth $124,584,000 after buying an additional 1,098,625 shares during the period. Finally, Schafer Cullen Capital Management Inc. boosted its holdings in GlaxoSmithKline by 66.5% in the 1st quarter. Schafer Cullen Capital Management Inc. now owns 1,870,961 shares of the pharmaceutical company’s stock worth $73,098,000 after buying an additional 747,423 shares during the period. Hedge funds and other institutional investors own 11.48% of the company’s stock.

In related news, major shareholder Plc Glaxosmithkline acquired 80,000 shares of the company’s stock in a transaction on Tuesday, July 17th. The stock was acquired at an average price of $12.50 per share, with a total value of $1,000,000.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired a total of 498,048 shares of company stock valued at $6,136,988 in the last three months. Insiders own 10.00% of the company’s stock.

GSK has been the subject of several recent analyst reports. Shore Capital raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday, July 27th. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Friday, June 8th. DZ Bank reaffirmed a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, June 14th. ValuEngine downgraded shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Friday, May 4th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Friday, July 20th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $41.57.

Shares of GlaxoSmithKline stock opened at $41.28 on Friday. The firm has a market capitalization of $103.02 billion, a P/E ratio of 14.33, a PEG ratio of 2.05 and a beta of 0.84. The company has a quick ratio of 0.61, a current ratio of 0.94 and a debt-to-equity ratio of 8.13. GlaxoSmithKline plc has a fifty-two week low of $34.52 and a fifty-two week high of $42.36.

GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 25th. The pharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.71 by $0.06. GlaxoSmithKline had a net margin of 5.51% and a return on equity of 159.74%. The business had revenue of $9.95 billion during the quarter, compared to the consensus estimate of $9.47 billion. sell-side analysts forecast that GlaxoSmithKline plc will post 2.94 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 11th. Shareholders of record on Friday, August 10th will be issued a dividend of $0.496 per share. This represents a $1.98 annualized dividend and a dividend yield of 4.81%. The ex-dividend date of this dividend is Thursday, August 9th. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 68.75%.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: Market Capitalization in the Stock Market

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.